Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
| Revenue (Most Recent Fiscal Year) | $18.22M |
| Net Income (Most Recent Fiscal Year) | $52.98M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 0.01 |
| Pre-Tax Margin (Trailing 12 Months) | 290.90% |
| Net Margin (Trailing 12 Months) | 290.81% |
| Return on Equity (Trailing 12 Months) | -90.20% |
| Return on Assets (Trailing 12 Months) | 331.20% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.13 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.10 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.95 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.64 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-7.62 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 53.96M |
| Free Float | 53.85M |
| Market Capitalization | $0.86M |
| Average Volume (Last 20 Days) | 0.67M |
| Beta (Past 60 Months) | -1.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.21% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.22% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |